Trial · NCT04504045
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
NCT04504045, Phase 1, Terminated, University of Southern Denmark
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes. Trials, record NCT04504045. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04504045
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
- NCT number
- NCT04504045
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 10 participants, actual
- Lead sponsor
- University of Southern Denmark
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin, Caffeine, Efavirenz, Losartan, Omeprazol, Metoprolol, Midazolam
- First posted
- 2020-08-07
- Last updated
- 2022-06-16
- Other registries' IDs
- eudract:2020-000162-42
Source ClinicalTrials.gov
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 3. | Baseline and Week 3. | Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 3 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4). |
| Primary | Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12. | Baseline and Week 12. | Change in activity of the drug metabolizing enzyme CYP3A4 following treatment with the glucose lowering drug metformin in 12 weeks. Assessment of the change is based on a change in the metabolic rate, which is the ratio between the concentration of midazolam and its primary metabolite is plasma (Probe drug for CYP3A4). |
| Secondary | Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 3. | Baseline and Week 3. | Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine. |
| Secondary | Change from Baseline in Metabolic Rate of Caffeine (CYP1A2) at Week 12. | Baseline and Week 12. | Change in activity of the drug metabolizing enzymes CYP1A2 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug caffeine. |
| Secondary | Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 3. | Baseline and Week 3. | Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz. |
| Secondary | Change from Baseline in Metabolic Rate of Efavirenz (CYP2B6) at Week 12. | Baseline and Week 12. | Change in activity of the drug metabolizing enzymes CYP2B6 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Efavirenz. |
| Secondary | Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 3. | Baseline and Week 3. | Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan. |
| Secondary | Change from Baseline in Metabolic Rate of Losartan (CYP2C9) at Week 12. | Baseline and Week 12. | Change in activity of the drug metabolizing enzymes CYP2C9 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Losartan. |
| Secondary | Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 3. | Baseline and Week 3. | Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 3 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole. |
| Secondary | Change from Baseline in Metabolic Rate of Omeprazole (CYP2C19) at Week 12. | Baseline and Week 12. | Change in activity of the drug metabolizing enzymes CYP2C19 following treatment with the glucose lowering drug metformin after 12 weeks. The change in activity is based on the metabolic rate for the probe drug Omeprazole. |
1 to 10 of 34Source ClinicalTrials.gov
See all 34 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04504045
GET https://conductscience.org/api/trials/v1/NCT04504045/registered?page=2